StageUnattributed VC - IV | Alive
Last Raised$160K | 14 yrs ago
About Timi3 Systems
Timi3 Systems, Inc., a biotechnology company, develops a non-invasive transcutaneous ultrasound system for the treatment of patients experiencing an acute myocardial infarction or heart attack. The company specializes in the non-invasive delivery of thrombolytic drugs that hasten the dissolution of thrombus during a myocardial infarction. Timi3 Systems, Inc. was founded in 1999 and is based in Santa Clara, California.
Missing: Timi3 Systems's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Timi3 Systems's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Timi3 Systems
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Timi3 Systems is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Timi3 Systems Frequently Asked Questions (FAQ)
When was Timi3 Systems founded?
Timi3 Systems was founded in 1999.
Where is Timi3 Systems's headquarters?
Timi3 Systems's headquarters is located at 3032 Coronado Drive, Santa Clara.
What is Timi3 Systems's latest funding round?
Timi3 Systems's latest funding round is Unattributed VC - IV.
How much did Timi3 Systems raise?
Timi3 Systems raised a total of $16.36M.
Who are the investors of Timi3 Systems?
Investors of Timi3 Systems include Venrock and U.S. Venture Partners.
Who are Timi3 Systems's competitors?
Competitors of Timi3 Systems include Longevica, Molmed, Cellerant Therapeutics, Asmacure, Transave and 12 more.
Compare Timi3 Systems to Competitors
Enox Biopharma is a biotechnology company that developed a drug eluting technology suitable for treatment of acute and antibiotic resistant ear infection in children.
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.
ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a high proportion of common surgical procedures causing pain and dysfunction in millions of patients worldwide.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.